BeOne Medicines (ONC) Return on Capital Employed (2016 - 2026)
BeOne Medicines (ONC) posted quarterly Return on Capital Employed of 10.46% for Q1 2026, up 1805.0% year-over-year from 0.55% in Q1 2025, and up 42.23% quarter-over-quarter from 7.35% in Q4 2025.
BeOne Medicines (ONC) Return on Capital Employed (2016 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Return on Capital Employed for 11 consecutive years, with 10.46% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 1805.0% year-over-year to 10.46%; the TTM figure through Mar 2026 stood at 10.46% (up 1805.0% YoY), while the FY2025 annual figure was 8.56%, up 2413.0% from the prior year.
- Return on Capital Employed grew to 10.46% in Q1 2026 per ONC's latest filing, from 7.35% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 10.46% in Q1 2026 and bottomed at 38.47% in Q1 2023.
- Historically, Return on Capital Employed has averaged 17.94% across 5 years, with a median of 20.04% in 2022.
- Annual changes were most pronounced in 2022 — Return on Capital Employed plunged 2177 bps — and 2025, when it soared 2727 bps.
- BeOne Medicines' Return on Capital Employed stood at 34.51% in 2022, then gained by 9 bps to 31.33% in 2023, then jumped by 50 bps to 15.52% in 2024, then jumped by 147 bps to 7.35% in 2025, then jumped by 42 bps to 10.46% in 2026.
- Business Quant data shows ONC's Return on Capital Employed at 10.46% in Q1 2026, 7.35% in Q4 2025, and 3.97% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -36.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.68% |
| Mar 31, 2026 | 10.46% |
| Dec 31, 2025 | 7.35% |
| Sep 30, 2025 | 3.97% |
| Jun 30, 2025 | -2.61% |
| Mar 31, 2025 | -7.59% |
| Dec 31, 2024 | -15.52% |
| Sep 30, 2024 | -23.29% |
| Jun 30, 2024 | -23.63% |
| Mar 31, 2024 | -28.48% |
| Dec 31, 2023 | -31.33% |
| Sep 30, 2023 | -29.76% |
| Jun 30, 2023 | -35.99% |
| Mar 31, 2023 | -38.47% |
| Dec 31, 2022 | -34.51% |
| Sep 30, 2022 | -20.04% |
| Jun 30, 2022 | -18.32% |
| Mar 31, 2022 | -17.24% |
| Dec 31, 2021 | -12.74% |
| Sep 30, 2021 | -32.97% |